Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc. (SYRS) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
syrs · pe ratio · data through Dec 31, 2023
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Syros Pharmaceuticals, Inc. (SYRS) measures how much investors pay for each dollar of the company's trailing earnings. SYRS's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of -$5.81.
Source: FMP · /ratios-ttm · /analyst-estimates · 2023-12-31
PE Ratio History
2013 – 2023 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Syros Pharmaceuticals, Inc.You SYRS | $0M | N/A | — | -$5.81 |
 Coeptis Therapeutics, Inc. COEP | $58M | N/A | — | -$2.81 |
 Dermata Therapeutics, Inc. DRMA | $1M | N/A | — | -$8.16 |
 Pasithea Therapeutics Corp. KTTA | $4M | N/A | — | -$2.91 |
 NKGen Biotech, Inc. Common Stock NKGN | $8M | N/A | — | -$1.54 |
 Holdco Nuvo Group D.G Ltd. Ordinary Shares NUVO | $6M | N/A | — | -$1.64 |
 Purple Biotech Ltd. PPBT | $0M | N/A | — | -$10992.95 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2023-12-31Latest FY2023 | — | $-5.81 | — | |
2022-12-31 FY2022 | — | $-7.49 | — | |
2021-12-31 FY2021 | — | $-13.84 | — | |
2020-12-31 FY2020 | — | $-18.25 | — | |
2019-12-31 FY2019 | — | $-18.76 | — | |
2018-12-31 FY2018 | — | $-19.07 | — | |
2017-12-31 FY2017 | — | $-21.26 | — | |
2016-12-31 FY2016 | — | $-37.60 | — | |
2015-12-31 FY2015 | — | $-120.45 | — | |
2014-12-31 FY2014 | — | $-54.25 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Syros Pharmaceuticals, Inc. (SYRS) measures how much investors pay for each dollar of the company's trailing earnings. SYRS's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of -$5.81.
Frequently asked questions
SYRS pe ratio · 6 questionsSYRS's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.00 and TTM EPS of -$5.81. Data sourced from Financial Modeling Prep via SYRS's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Syros Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09